Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Sarepta's first quarter 2026 earnings results call. As a reminder, today's program is being recorded. I would now like to turn the call over to Tam Thornton, Sarepta's Director of Investor Relations. Please go ahead. Thank you, Antoine, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the first quarter of 2026. The press release, along with our presentation slides and supplementary information, will be available on the investor section of our company website. We plan to file our Form 10-Q for the quarter today with the SEC. Joining me on the call today are Doug Ingram, our CEO, Dr. Louise Rodino-Claypack, President of Research and Development in Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our chief financial officer. Additionally, joining us in the Q&A portion of the call are Ian Estepan, president and chief operations officer, and Dr. James Richardson, our chief medical officer. Before we begin the formal remarks, I would like to note that during this call, we will be making a number of forward-looking statements. Please refer to slide two of our presentation to view the formal text of these safe harbor statements. These statements involve varying risks and uncertainties, many of which are beyond Syrepta's control. Actual results could materially differ from these forward-looking statements, and such risks can adversely affect our business, our results of operations, and the trading crisis throughout this common stock. We strongly encourage all listeners to review the company's most recent SEC filings for a detailed description of these applicable risks. The replica explicitly states that it does not undertake any obligation to publicly update...